chufangao/CTO huggingface dataset:
Clinical trial NCT03851705: A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
Official title: A Two-Part (Double-Blind Placebo Controlled/Open-Label) Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Subjects With Homozygous Familial Hypercholesterolemia (Hofh) (ORION-5)
Acronym: ORION-5
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 56.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-02-06
Primary completion date: 2020-03-02
Completion date: 2021-09-09
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Clinical trial NCT05457530: Doravirine and Weight Gain in Antiretroviral Naive
Official title: Effect of Modified, Rapid-start, DOR/3TC/TDF or DOR + FTC/TAF or BIC/FTC/TAF on Body Weight and Composition, Metabolic Risk Parameters, and Measures of Bone Strength in Treatment-Naïve Black and Hispanic Women With HIV-1 Infection
Acronym: DAWN
Sponsor: Prism Health North Texas (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Due to No/Low enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-08-01
Primary completion date: 2023-05-03
Completion date: 2023-05-03
Plan to share individual participant data: NO
Clinical trial NCT04767373: Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
Official title: A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 3632.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-07
Primary completion date: 2024-07-09
Completion date: 2024-07-09
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT05218096: Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
Sponsor: Alexion Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 70.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-04-27
Primary completion date: 2023-11-30
Completion date: 2024-04-03
Plan to share individual participant data: YES
IPD sharing description: Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Clinical trial NCT03919799: KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis
Official title: A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision due to slow enrollment and strategic consideration; not driven by any safety concerns.
Enrollment: 36.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-06-26
Primary completion date: 2022-08-09
Completion date: 2023-02-17
Baseline population: Analysis was performed on modified intent-to-treat (mITT) population which included all participants who received at least one dose of the study drug.
Limitations and caveats: The study was terminated early by the Sponsor due to slow enrollment and strategic consideration and was not driven due to any safety concerns.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT05363644: BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy
Official title: Treatment Protocol With BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy: A Prospective Open Label Single-Center Study
Sponsor: AdventHealth (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Study was withdrawn due to lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-04-01
Primary completion date: 2023-12-31
Completion date: 2024-06-30
Plan to share individual participant data: NO
IPD sharing description: De-identified information may be utilized in teachings and/or publication as it related to this research.
Clinical trial NCT03692780: Careseng 1370 for Chemotherapy-Induced Myelosuppression
Official title: A Phase I Dose-Finding Followed by Phase IIa Randomized, Double-Blind, Placebo-Controlled, Parallel, Add-on to Cisplatin Plus Docetaxel Study to Evaluate the Safety, Tolerability and Efficacy Profiles of Careseng 1370 to Treat Chemotherapy-Induced Myelosuppression in Advanced Non-Small Cell Lung Cancer (NSCLC) Subjects
Sponsor: Careseng Biotech Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: At sponsor's discretion
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-03-31
Primary completion date: 2021-03-31
Completion date: 2021-06-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03903822: Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
Official title: A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06700841 CREAM APPLIED ONCE OR TWICE DAILY FOR 6 WEEKS IN PARTICIPANTS WITH MILD OR MODERATE ATOPIC DERMATITIS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 292.0 (ACTUAL)
Number of arms: 8.0
Start date: 2019-05-13
Primary completion date: 2020-05-07
Completion date: 2020-05-07
Baseline population: Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests
Clinical trial NCT04382651: Study of Efficacy and Safety of MAS825 in Patients With COVID-19
Official title: A Phase 2, Randomized, Placebo-controlled, Participant and Investigator Blinded, Multi-center Study to Assess Efficacy and Safety of MAS825 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function
Acronym: MAS-COVID
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 140.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-11
Primary completion date: 2021-01-06
Completion date: 2021-04-21
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Clinical trial NCT03761953: Oritavancin for Staphylococcus Aureus Infections in Opioid Users
Official title: A Pilot Proof of Concept Single-Center Study of the Use of Oritavancin in Systemic Staphylococcus Aureus Infections in Patients With Opioid Use Disorder
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: COVID 19 pandemic
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-01
Primary completion date: 2022-03-24
Completion date: 2022-03-24
Plan to share individual participant data: NO
Clinical trial NCT03103750: Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD
Official title: Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Study of Stimulant-induced Dopamine Release Using [11C]-PHNO PET in Healthy Humans
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-15
Primary completion date: 2023-01-17
Completion date: 2023-01-17
Baseline population: Overall sample prior to randomization to crossover sequence.
Plan to share individual participant data: NO
Clinical trial NCT04826432: Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis
Official title: Efficacy and Feasibility of Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis - a Phase II Randomized Multicentric Trial
Acronym: PASIREOCHIP
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: No more experimental drugs available
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-03
Primary completion date: 2024-02-07
Completion date: 2024-02-07
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03658109: Lidocaine Infusion or Quadratus Lumborum Block and Intrathecal Morphine, Versus Intrathecal Morphine Alone
Official title: Systemic Lidocaine Infusion or Quadratus Lumborum Block (in Addition to Intrathecal Morphine) Versus Intrathecal Morphine Alone as Part of a Gynecology-Oncology Surgery Early Recovery Protocol
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Recruitment challenges due to COVID-19
Enrollment: 1.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-09-24
Primary completion date: 2021-05-04
Completion date: 2021-05-04
Clinical trial NCT03996252: Combination Topical Therapy for Treatment of Scalp Actinic Keratoses
Official title: Combination Calcipotriene 0.005% Foam and Fluorouracil 5% Cream for the Treatment of Actinic Keratoses on the Scalp
Sponsor: Tulane University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: The study team was not able to start the study and they never completed the IRB submission, so the study was terminated.
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-01
Primary completion date: 2020-01-01
Completion date: 2020-06-08
Plan to share individual participant data: NO
Clinical trial NCT03502746: Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Official title: Phase II Study of Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma:Hoosier Cancer Research Network LUN15-299
Sponsor: Hoosier Cancer Research Network (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: IRB Study Closure
Enrollment: 34.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-06-26
Primary completion date: 2022-05-11
Completion date: 2023-11-09
Plan to share individual participant data: NO
Clinical trial NCT02468232: Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction
Official title: A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction.
Acronym: PARALLEL-HF
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 225.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-06-15
Primary completion date: 2019-02-08
Completion date: 2021-02-18
Baseline population: The Full Analysis Set (FAS) consists of all randomized patients with the exception for those patients who have not been qualified for randomization (mis-randomized) and have not received investigational drug, but have been inadvertently randomized into the study.
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03220178: Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy
Official title: PRECYCLE: Multicenter, Randomized Phase IV Intergroup Trial to Evaluate the Impact of eHealth-based Patient Reported Outcome (PRO) Assessment on Quality of Life in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib and an Aromatase Inhibitor- or Palbociclib and Fulvestrant
Acronym: PRECYCLE
Sponsor: Palleos Healthcare GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Due to COVID-19 pandemic, study cannot be finished in planned timeframe.
Enrollment: 532.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-07-24
Primary completion date: 2021-12-07
Completion date: 2021-12-07
Plan to share individual participant data: NO
Clinical trial NCT03164993: Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer
Official title: ALICE: a Randomized Placebo-controlled Phase II Study Evaluating Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer
Acronym: ALICE
Sponsor: Oslo University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 68.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-01
Primary completion date: 2023-04-25
Completion date: 2023-09-30
Plan to share individual participant data: NO
Clinical trial NCT04212650: Losartan to Improve Hip Microfracture
Official title: Biologically Regulated Marrow Stimulation by Blocking Fibrosis to Improve Cartilage Repair: A Randomized Double-Blind, Placebo-Controlled Study
Sponsor: Steadman Philippon Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: redesigned trial using another placebo controlled drug
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-07
Primary completion date: 2020-12-04
Completion date: 2020-12-04
Baseline population: One (1) participant was enrolled in the study and subsequently randomized to the Losartan arm.
Limitations and caveats: Per opinion of the Principal Investigator, Losartan is now clinically indicated as a standard of care post-operative therapy for patients undergoing hip microfracture surgeries. The study was terminated early, resulting in a singular subject enrolled for data analysis. The subject elected to withdraw from the study prior to the first follow-up data collection timepoint.
Plan to share individual participant data: NO
Clinical trial NCT03228186: Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Official title: Phase II Trial of Pevonedistat (TAK-924) Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Sponsor: University of Michigan Rogel Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Pharmaceutical company discontinued the study drug.
Enrollment: 40.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-05
Primary completion date: 2021-11-04
Completion date: 2021-11-04
Baseline population: 9 patients were screen failed
Clinical trial NCT04902950: TXA in the Reduction of Post-Op Hematoma and Seroma in Patients Undergoing Panniculectomy or Abdominoplasty
Official title: Role of Tranexamic Acid (TXA) in the Reduction of Post-operative Hematoma and Seroma in Patients Undergoing Panniculectomy or Abdominoplasty, a Pilot Study.
Sponsor: The Reading Hospital and Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Logistics
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-17
Primary completion date: 2021-05-06
Completion date: 2021-05-06
Plan to share individual participant data: NO
Clinical trial NCT04933240: Tamoxifen Versus Estradiol for Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Pilot Trial
Official title: Tamoxifen Versus Estradiol in the Prevention of Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Controlled Pilot Trial
Sponsor: Virginia Commonwealth University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Anticipated funding was not received
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-05-31
Primary completion date: 2024-06-30
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT03598777: Dysport in Vulvodynia Phase II Study
Official title: A Phase II, Multicentre, Double-blind, Randomised, Placebo Controlled, Dose Escalation and Dose Finding Study to Evaluate the Efficacy and Safety of Dysport in Vulvodynia Patients
Acronym: DYVINIA
Sponsor: Ipsen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: lack of efficacy
Enrollment: 60.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-06-11
Primary completion date: 2021-01-21
Completion date: 2021-01-21
Baseline population: All randomised participants were included in the baseline analysis.
Limitations and caveats: After all participants completed Week 12, a Data Review Committee (DRC) recommended: No safety concerns noted in review of all available data. Efficacy cannot be assessed due to the small sample size of cohorts. The DRC would recommend that Stage 1 is not used to make an efficacy assessment; therefore, there is no justification to increase the dose, nor to move to Stage 2. Thus, sponsor terminated the study early; the decision was not related to any safety/tolerability concerns with Dysport.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04723537: Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
Official title: Phase 2/3 Study of Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
Sponsor: RedHill Biopharma Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Part A complete; corporate decision made to cancel Part B.
Enrollment: 61.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-02-16
Primary completion date: 2021-12-28
Completion date: 2021-12-28
Plan to share individual participant data: NO
Clinical trial NCT01673867: Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC
Official title: An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Acronym: CheckMate057
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 582.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-11-02
Primary completion date: 2015-02-05
Completion date: 2021-12-17
Baseline population: All randomized participants
Clinical trial NCT04502472: Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma
Official title: Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma Collected From Individuals With Documented Infection and Recovery From COVID-19 (SARS-CoV-2)
Acronym: Inova-CCP
Sponsor: Inova Health Care Services (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: FDA gave emergency use approval to COVID-19 convalescent plasma on 08/24/2020
Enrollment: 109.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-06
Primary completion date: 2020-09-30
Completion date: 2020-09-30
Plan to share individual participant data: NO
Clinical trial NCT05184218: Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19
Official title: A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Intranasal Plus Intraoral IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19
Sponsor: IGM Biosciences, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor Decision
Enrollment: 26.0 (ACTUAL)
Number of arms: 7.0
Start date: 2022-01-20
Primary completion date: 2022-05-06
Completion date: 2022-07-04
Clinical trial NCT04388709: Interferon Lambda Therapy for COVID-19
Official title: A Randomized Phase 2 Trial of Peginterferon Lambda-1a (Lambda) for the Treatment of Hospitalized Patients Infected With SARS-CoV-2 With Non-critical Illness
Sponsor: Icahn School of Medicine at Mount Sinai (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Due to the number of competing trials at their site, the study team has closed enrollment and withdrawn this trial.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-30
Primary completion date: 2021-02-05
Completion date: 2021-02-05
Plan to share individual participant data: NO
Clinical trial NCT03453541: Ketorolac Use in Pediatric Patients Undergoing Tonsillectomy
Official title: A Randomized, Double-blinded, Placebo-controlled Study of Ketorolac Use in Pediatric Patients Undergoing Tonsillectomy
Sponsor: Albany Medical College (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Limited recruitment resources.
Enrollment: 214.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-21
Primary completion date: 2022-11-01
Completion date: 2022-11-01
Plan to share individual participant data: NO
Clinical trial NCT01541215: Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes
Official title: Efficacy and Safety of Liraglutide in Combination With Metformin Versus Metformin Monotherapy on Glycaemic Control in Children and Adolescents With Type 2 Diabetes
Acronym: Ellipse™
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 135.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-11-13
Primary completion date: 2017-11-15
Completion date: 2020-05-20
Baseline population: Full analysis set (FAS) - included all randomised subjects receiving at least one dose of liraglutide/placebo
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com